Abstract
Early detection of pancreatic cancer has been a long-standing challenge in determining prognosis and management of the deadly disease. Although the incidence of pancreatic cancer is low (2% of all malignancies), it is the fourth leading cause of deaths attributable to cancer in the U.S. A major cause for the high mortality rate, which exceeds 85%, is the difficulty in diagnosing the disease early in its development. The relative lack of reliable diagnostic tools to screen patients who are asymptomatic prior to the aggressive progression of disease has been the primary contributing factor in the high mortality rate in this patient population. Indeed, 80-90% of patients with pancreatic cancer have relatively small unresectable tumors at the time of diagnosis. Therefore, there is an unmet need for a highly sensitive diagnostic imaging modality to detect early-stage pancreatic cancer, as this may save the lives of many thousands of patients. Many literature reviews have been published on various aspects of pancreatic cancer, including biology, screening, and therapy; however, limited information is available on early detection, especially the use of highly sensitive modalities such as positron emission tomography (PET). Current [18F]FDG/PET imaging combined with CT (PET/CT) lacks the necessary sensitivity and specificity for detection of small lesions (~2-3 mm) of pancreatic cancer that may be resectable and curable. Furthermore, accumulation of [18F]FDG in inflammatory tissue is a major problem; therefore, an appropriate PET tracer that is both highly sensitive and specific for carcinoma is necessary for PET imaging of early stage pancreatic cancer. This review focuses on early detection of pancreatic cancer by PET, including new targets and the development and application of new PET tracers.
Keywords: [18F]-lactose, HIP/PAP, molecular imaging, PDAC, PET.
Current Medicinal Chemistry
Title:Current and Future Trends in Early Detection of Pancreatic Cancer: Molecular Targets and PET Probes
Volume: 22 Issue: 29
Author(s): Mian M. Alauddin and Louis De Palatis
Affiliation:
Keywords: [18F]-lactose, HIP/PAP, molecular imaging, PDAC, PET.
Abstract: Early detection of pancreatic cancer has been a long-standing challenge in determining prognosis and management of the deadly disease. Although the incidence of pancreatic cancer is low (2% of all malignancies), it is the fourth leading cause of deaths attributable to cancer in the U.S. A major cause for the high mortality rate, which exceeds 85%, is the difficulty in diagnosing the disease early in its development. The relative lack of reliable diagnostic tools to screen patients who are asymptomatic prior to the aggressive progression of disease has been the primary contributing factor in the high mortality rate in this patient population. Indeed, 80-90% of patients with pancreatic cancer have relatively small unresectable tumors at the time of diagnosis. Therefore, there is an unmet need for a highly sensitive diagnostic imaging modality to detect early-stage pancreatic cancer, as this may save the lives of many thousands of patients. Many literature reviews have been published on various aspects of pancreatic cancer, including biology, screening, and therapy; however, limited information is available on early detection, especially the use of highly sensitive modalities such as positron emission tomography (PET). Current [18F]FDG/PET imaging combined with CT (PET/CT) lacks the necessary sensitivity and specificity for detection of small lesions (~2-3 mm) of pancreatic cancer that may be resectable and curable. Furthermore, accumulation of [18F]FDG in inflammatory tissue is a major problem; therefore, an appropriate PET tracer that is both highly sensitive and specific for carcinoma is necessary for PET imaging of early stage pancreatic cancer. This review focuses on early detection of pancreatic cancer by PET, including new targets and the development and application of new PET tracers.
Export Options
About this article
Cite this article as:
Alauddin M. Mian and De Palatis Louis, Current and Future Trends in Early Detection of Pancreatic Cancer: Molecular Targets and PET Probes, Current Medicinal Chemistry 2015; 22 (29) . https://dx.doi.org/10.2174/0929867322666150821094015
DOI https://dx.doi.org/10.2174/0929867322666150821094015 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Class II Nuclear Receptors in Liver Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Antioxidant Potential of Solvent Partitioned Extraction from Aqueous Extract of Gracilaria Tenuistipitata
Current Organic Chemistry Cyclopentenyl Cytosine (CPEC): An Overview of its in vitro and in vivo Activity
Current Cancer Drug Targets Recent Patents Therapeutic Agents for Cancer
Recent Patents on Anti-Cancer Drug Discovery Caffeic Acid, A Versatile Pharmacophore: An Overview
Mini-Reviews in Medicinal Chemistry Caffeine; the Forgotten Potential for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Molecular Mechanisms Regulating Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1
Current Cancer Therapy Reviews Selected Players in the Inflammation Cascade and Drugs That Target These Inflammation Genes Against Metastasis
Anti-Cancer Agents in Medicinal Chemistry The Dual Role of Tumor Necrosis Factor (TNF) in Cancer Biology
Current Medicinal Chemistry Cytotoxic, Apoptotic and DNA Synthesis Inhibitory Effects of Some Thiazole Derivatives
Letters in Drug Design & Discovery Alteration of Hepatic Proinflammatory Cytokines is Involved in the Resveratrol-Mediated Chemoprevention of Chemically-Induced Hepatocarcinogenesis
Current Pharmaceutical Biotechnology Possibilities of Two-Dimensional Gel Electrophoresis in the Understanding of Human Disease
Current Proteomics Tyrosine Kinase Inhibitors: A Potential Approach to the Treatment of Hepatocellular Carcinoma
Current Pharmaceutical Design Lectin-Carbohydrate Interactions: Implications for the Development of New Anticancer Agents
Current Medicinal Chemistry Receptor Tyrosine Kinases: The Main Targets for New Anticancer Therapy
Current Drug Targets Invasive Aspergillosis: New Insights into Disease, Diagnostic and Treatment
Current Pharmaceutical Design Xanthine Derivatives as Agents Affecting Non-dopaminergic Neuroprotection in Parkinson’s Disease
Current Medicinal Chemistry Gold - Old Drug with New Potentials
Current Medicinal Chemistry Towards a Gene Therapy Clinical Trial for Epidermolysis Bullosa
Reviews on Recent Clinical Trials